iShares Biotechnology ETF
IBB
- $167.56
- 1.11
- 0.66%
iShares Biotechnology ETF IBB Strategy
The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector.
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
The investment objective & strategy is a summary of the investment's principal strategy as written in the prospectus. This information is pulled from the most recent product disclosure document.
ETFs News & Analysis
etfs
How a professional picks an ETF
Morningstar’s Chief Investment Officer Matt Wacher shares his perspective.
etfs
Young & Invested: The ETF valuation mistake investors often make
Why ETF value hunting is an illusion.
etfs
What Australian investors are buying and selling
The Australian ETF and managed fund landscape at the end of 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,818.53 | 174.96 | -2.19% |
| DAX 40 | 23,153.99 | 437.04 | -1.85% |
| Dow JONES (US) | 46,642.72 | 858.83 | -1.81% |
| FTSE 100 | 10,147.21 | 137.54 | -1.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,090.37 | 297.31 | -1.33% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,098.83 | 519.06 | -3.81% |
| S&P 500 | 6,639.14 | 100.88 | -1.50% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |